Keywords
Propranolol, hemangioblastomas, Von Hippel Lindau disease, case report
This article is included in the Rare diseases collection.
Propranolol, hemangioblastomas, Von Hippel Lindau disease, case report
A 33-year-old Caucasian female who was diagnosed with Von Hippel Lindau (VHL) disease in 2002. Her mother suffered sudden death in 2002; and a diagnosis of VHL was made at her autopsy. Therefore, the patient was studied by a neurologist, and one hemangioblastoma (HB) of 2cm in size was observed at the medulla during magnetic resonance imaging (MRI). The patient exhibited no symptoms; however, she underwent surgery in 2003 for the risk of complications due to the size of the HB. The patient’s recovery was uneventful. Since then an annual MRI of the central nervous system (CNS) has been performed.
From 2009, a progressive tumor growth of two HBs in the medulla was observed, which was checked annually by the neurosurgeon because the patient was asymptomatic.
Furthermore, the patient suffered from occasional migraine episodes since 2003. She presented with a worsening of her previous migraine, having headache attacks everyday since October 2013. After discussing the various treatment options, the patient opted for propranolol at increasing doses up to 120 mg per day starting in March of 2014. At the 3 month follow-up visit after starting propranolol, the patient reported a slight reduction in her migraines; however the dose was increased to 160 mg per day because patient still suffered more than 10 migraine episodes per month. No adverse events were observed during that period of time. At the 9 month follow-up visit, 6 months after 160mg per day of intake, she showed a significant improvement. During propranolol treatment, the patient underwent a cerebral and spinal cord MRI in October 2014, which showed no changes from the previous scan performed one year before. The patient continued to take propranolol; however, side effects appeared (orthostatic hypotension) in March 2015 (after 12 months of propranolol treatment) and necessitated a slow decrease in propranolol dosage until the treatment was stopped in July 2015. Subsequently, the patient’s migraine did not worsen; however, a clear growth in the medullary HBs was shown by control MRI (Figure 1) in October 2015. The patient required surgery in January 2016, due to an increase in tumor size observed in MRI. Since then the patient has remained asymptomatic.
VHL disease, a rare autosomal dominant disorder, is caused by the deletion or mutation of the VHL tumor suppressor gene1–3. It has been reported that the absence of functional VHL protein, which occurs in the disease, often leads to the formation of highly vascular tumors, such as hemangioblastomas (HBs)4–6. Although some antiangiogenic therapies have been tried7,8, there are currently no effective pharmacological therapies for HBs, thus surgery remains the standard procedure9. Our patient was monitored by means of an annual MRI to check the growth of the tumors. The images were reviewed by the neurosurgeon in order to determine if the hemangioblastomas were of sufficient size for safe surgery.
Propranolol is a beta-blocker that is offered as first line treatment in the prophylaxis of migraine10. It is also used for the treatment of essential tremor11, hypertension and some cardiac diseases. In our case, the patient suffered worsening of her migraine and propranolol administration was indicated. Propranolol has also a proven efficacy in infantile hemangioma treatment12. Furthermore, propranolol has shown an antiangiogenic effect13, and a recent publication indicates that propranolol reduces the viability of HBs cultivated in vitro14. In the light of these data and after discussing the options with the patient, she decided to continue taking propranolol; however due to symptomatic orthostatic hypotension, the patient had to stop. Unfortunately, the HBs showed clear growth in MRI after stopping treatment.
In summary, propranolol treatment appeared to inhibit growth of the HBs after several years of steady progression, as seen in the MRI results. Tumor growth commenced again once the treatment with propranolol was interrupted. Our case study suggests that propranolol can delay the growth of hemangioblastomas in the CNS.
Written informed consent for publication of the clinical details and images was obtained from the patient.
ABPM and GSH wrote the paper. TSM was the physician responsible for the patient in this case report. All authors have participated in the concept and design/analysis and interpretation of data, drafting and revising the manuscript, and they have given final approval for the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the background of the case’s history and progression described in sufficient detail?
Partly
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly
Is the case presented with sufficient detail to be useful for other practitioners?
No
Competing Interests: No competing interests were disclosed.
Is the background of the case’s history and progression described in sufficient detail?
Partly
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly
Is the case presented with sufficient detail to be useful for other practitioners?
Partly
References
1. Lonser RR, Butman JA, Huntoon K, Asthagiri AR, et al.: Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease.J Neurosurg. 2014; 120 (5): 1055-62 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Molecular and clinical genetics, Von Hippel-Lindau disease
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 13 Mar 17 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)